Trichlormethiazide sodium is an orally active thiazide diuretic. Trichlormethiazide sodium shows antihypertensive effect. In acute renal failure rats model, Trichlormethiazide sodium increases urine volume (UV), Na and K excretion and tends to improve the creatinine clearance (CCRE).

Trichlormethiazide (1 mg/kg; p.o.; once) sodium increases urinary volume, sodium and potassium excretion in rats [1]. Trichlormethiazide (10 mg/kg, i.v.; daily for 5 days) sodium significantly reduces mean arterial pressure (MAP) within 24 h in high salt intake (HS) rats receiving angiotensin II, but does not affect MAP in any other group [2]. Animal Model: Male Wistar rats, weighing 170-300 g [1] Dosage: 1 mg/kg Administration: Oral administration, once Result: Significantly increased potassium excretion in normal rats. Significantly increased urinary volume, sodium and potassium excretion in cisplatin-induced ARF (acute renal failures) rats. Animal Model: Male Sprague-Dawley rats (350-450 g) [2] Dosage: 10 mg/kg Administration: Intravenous injection, daily, for 15 days Result: Produced a significant fall in MAP in rats on combined angiotensin II and high salt intake.